Nab-paclitaxel as First Line Treatment for NSCLC in Elderly Patients More Than 75 Years Old

MLA

David Feller Kopman, et al. “Nab-Paclitaxel as First Line Treatment for NSCLC in Elderly Patients More Than 75 Years Old.” Journal of Cancer, vol. 8, no. 9, June 2017, pp. 1673–78. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....481893a6d9064420cb30c4da7d756a07&authtype=sso&custid=ns315887.

APA

David Feller Kopman, Paul Zarogoulidis, Georgia Trakada, Lonny Yarmus, Susana Papadopoulou, Haidong Huang, Aggeliki Rapti, Yan Gao Man, Kosmidis Cristoforos, Eleni Faniadou, Wolfgang Hohenforst-Schmidt, Chong Bai, Dimitris Petridis, & Ellada Eleftheriadou. (2017). Nab-paclitaxel as First Line Treatment for NSCLC in Elderly Patients More Than 75 Years Old. Journal of Cancer, 8(9), 1673–1678.

Chicago

David Feller Kopman, Paul Zarogoulidis, Georgia Trakada, Lonny Yarmus, Susana Papadopoulou, Haidong Huang, Aggeliki Rapti, et al. 2017. “Nab-Paclitaxel as First Line Treatment for NSCLC in Elderly Patients More Than 75 Years Old.” Journal of Cancer 8 (9): 1673–78. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....481893a6d9064420cb30c4da7d756a07&authtype=sso&custid=ns315887.